

Clinical and Resistance Pattern of Coagulase Negative Staphylococci

Shaween Omed Faiq*
Sherko Ali Omer**

Abstract

Background and Objectives: Coagulase-negative staphylococci are commensal bacteria inhabiting human. Isolation of these bacteria from healthcare-associated and community infections is increasingly observed with resistance response to many antibiotics. The study aimed to identify the clinical and antimicrobial resistance pattern of coagulase-negative staphylococci isolated from various healthcare-associated and community-acquired infections.

Methods: This cross-sectional study was conducted in Shar Teaching Hospital and San Clinical Laboratory for a period of one year starting from 1st of November 2019. Isolated coagulase-negative staphylococci were collected from various hospitals and clinical laboratories. The isolate species were confirmed by several tests including VITEK[®] 2. VITEK[®] 2 systems was also used to determine the susceptibility to different antibiotics including cefoxitin, oxacillin gentamicin, linezolid, and glycopeptide agents' teicoplanin and vancomycin which were tested also by E-test.

Results: Coagulase-negative staphylococci were isolated from urine specimens (23%), followed by blood samples (20%), sterile body fluids (12%), and others. From one hundred isolates, the most common species of coagulase-negative staphylococci were *Staphylococcus epidermidis* (57%), *Staphylococcus haemolyticus* (24%), *Staphylococcus hominis* (8%), and others. The isolates showed high degree of resistance to benzyl penicillin (92%), oxacillin (85%), and cefoxitin (83%). No resistance to linezolid, tigecycline, and glycopeptides was detected.

Conclusion: *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* were the main coagulase-negative staphylococci isolates from several healthcare-associated infections such as bloodstream and urinary tract infection. Most of the isolates showed resistance responses to benzyl penicillin, oxacillin, and cefoxitin, while they were susceptible to glycopeptides, linezolid, and tigecycline, but intermediate response to glycopeptide was also observed.

Key words: Antimicrobial resistance, Coagulase negative Staphylococci, Glycopeptides.

Introduction

Coagulase-negative staphylococci (CoNS) are commensal bacteria inhabiting the anterior nares and the skin of humans.¹ They include Gram-positive aerobic cocci that lack coagulase enzyme, hence called CoNS, in contrast to coagulase Producing-*Staphylococcus aureus* which is a constant human pathogen.² Although CoNS are considered as harmless; over the last few

years there has been an increased incidence of healthcare-associated and community-acquired infections caused by CoNS.³ Currently, the genus *Staphylococcus* comprise at the minimum 40 species of Gram-positive catalase-positive cocci, including in recent time, the proposed *S. microti*. Among the CoNS subsets, 18 species have been

* MBChB, KHCMS Candidate, Pathology, Clinical Microbiology. College Medicine, University of Sulaimani, Kurdistan Region, Iraq.

**MBChB, MSc, PhD. Department of Microbiology, College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.

Correspondent author: Shaween Omed Faiq, Email: shaweenomed@gmail.com

isolated from humans, but, until now, only five species of CoNS have frequently been associated with nosocomial spread. These are; *S. epidermidis*, *S. haemolyticus*, *S. warneri* and *S. hominis*, and *S. lugdunensis*.⁴ Coagulase-negative staphylococci have an established role in infections of the bloodstream, urinary tract, surgical sites, prosthetic devices and shunts.³ Coagulase-negative staphylococci infections mainly result from hospitalization.⁵ Antimicrobial resistance has always been an important problem challenging the treatment of CoNS infections. CoNS species associated with human infections are usually resistant to β -lactams as well as other antibiotics, including aminoglycosides, quinolones, macrolides and tetracyclines.^{6,7} Antibiotic resistance is mainly due to genes carried on a plasmid such those found in methicillin-resistant CoNS strains.⁸ Resistance to glycopeptides can also be expressed heterogeneously by methicillin-resistant strains of both *S. aureus* (MRSA)⁹ and CoNS.¹⁰ About 80–90% of CoNS isolates associated with hospital infections were found to be methicillin-resistant coagulase-negative staphylococci.¹¹ The distinction between oxacillin-susceptible

and oxacillin-resistant strains is a useful clue for proper use of vancomycin in the hospital setting and to keep it as a reserve drug for serious infections caused by oxacillin-resistant strains.¹² Vancomycin is one of the most commonly used cell wall-active agents that retains activity, and is an alternative drug of choice for treatment of infections with resistance strains.¹³ Wide spread use of glycopeptides has led recently to emergence of CoNS isolates with decreased susceptibility of glycopeptides, displaying a minimum inhibitory concentration (MIC) of 4-8 mg/L for vancomycin, and MIC 8-16 for teicoplanin.¹ The MICs of teicoplanin have a tendency to be distributed over an increasingly wide range, while vancomycin MICs have remained more stable.¹⁰ Few studies detected vancomycin resistance in staphylococci.¹⁴ Reduced susceptibility to glycopeptides has been reported more commonly among *S. haemolyticus* than among *S. epidermidis*.^{10,15} The aim of the study is to identify the clinical and antimicrobial resistance pattern of different coagulase-negative staphylococci isolated from various healthcare-associated and community-acquired infections.

Materials and methods

This cross-sectional study was conducted in Shar Teaching Hospital and San Clinical Laboratory for a period of one year starting from 1st of November 2019. Presumptive CoNS isolates from various clinical samples were collected. The isolates were from patients admitted to hospital and patients attending outpatient departments and healthcare laboratories. Coagulase-negative staphylococci were regarded a significant cause of bacteremia when the same CoNS strain was isolated two or more times from blood culture sample within five days; when one blood culture sample yielded growth of CoNS, then at least two clinical parameters was taken into consideration; body temperature $>38^{\circ}\text{C}$ or $<36^{\circ}\text{C}$, elevated CRP, or systolic blood pressure <90 mmHg.¹² Automated

blood culture system (BACT/ALERT[®] 3D, bioMerieux) was used to detect growth in blood samples. The isolates were and transported and processed the same day by cultivating them on blood agar (Condalab), incubated at 37°C for 18-24 hours. The cultivated isolates were confirmed based on colony characteristics, Gram stain features, positive catalase test and negative tube coagulase test.¹⁶ CoNS species were identified with VITEK[®] 2 system (bioMerieux) using VITEK[®] 2 GP ID card.¹² Glycerol isolates were stocked according to Khosravi et al. and stored at -80°C for further uses.¹⁷ Analysis of susceptibility to antimicrobial agents was performed according to broth microdilution methods as described by the National Committee for Clinical

Laboratory Standards by using the VITEK[®] 2 AST-P592, and AST-P580 cards. The following antimicrobial were tested; benzylpenicillin, oxacillin, cefoxitin gentamycin, moxifloxacin, erythromycin, clindamycin, linezolid, teicoplanin, vancomycin, tetracycline, tigecycline, rifampicin, and trimethoprim/sulfamethoxazole.¹⁸ Standard E-test was performed on Mueller Hinton agar (Condalab) according to NCCLS.¹⁸ Standard E-test, is a gradient of antibiotic concentrations on a plastic strip, it is used to determine the Minimum Inhibitory Concentration (MIC) of that antibiotic.¹⁹ E-test strips for vancomycin and

teicoplanin 0.016–256 mg/L (Liofilchem[®]) were used. Agar plates were incubated at 35°C, the test was read after 24 hours and MIC was determined. Inducible clindamycin test for CoNS isolates was analyzed based on VITEK[®]2 system using standard AST-GP cards in accordance with the manufacturer’s protocol. Data entry was done using Microsoft excel and statistical analysis was performed using stata software 12; (T test, chi square) tests was performed. The research was approved by ethical committee of Kurdistan Higher Council of Medical Specialties.

Results

In this study one hundred confirmed CoNS isolate were proceeded and tested. Fifty-five of the isolates were taken from patients admitted to hospital and 45 isolates were from outpatient clinics. Forty-eight isolates were from male patients aged from four to 77 years, while 52 isolates were from female patients aged from one to 75 years Table (1). All the

patients from the hospitalized group (n=55) had medical interventions, while in the outpatient group, 6 out 45 (15.3%) had intervention (intravenous cannula). CoNS were isolated from urine specimens (23%), followed by blood samples (20%), sterile body fluids (12%), tip of the central venous catheter, other specimens Table (1).

Table (1): Patients characteristics and source of CoNS isolates.

Variable		n=100	Inpatient (n=55)	Outpatient (n=45)	p-value*
Sex and age	Male	48	29	19	0.2955
	age (4-77 y), \bar{x} 45.1 y				
	Female	52	26	26	
	age (1-75 y), \bar{x} 42.03 y				
Antibiotics used	Yes	55	36	19	< 0.001
	No	45	9	36	
Intervention	Yes	61	55	6	< 0.001
	No	39	0	39	
Specimen	Urine	23	3	20	
	Blood	20	20	0	
	Sterile body fluid	12	1	11	
	Vascular Catheter	11	11	0	
	Wound swab	9	4	5	
	CSF	7	7	0	
	High vaginal swab	5	0	5	
	Respiratory	5	5	0	
	Others**	8	4	4	

* Chi-Square test

** Other samples included ear swab, pus, and external ventricular drain shunt.

Table (2) shows the isolated species of CoNS from clinical specimens. *S. epidermidis* follows by *S. haemolyticus* were the commonest isolates. *S. epidermidis* was isolated from 9 (45%) of blood specimens and from 9 (75%) of

sterile body fluids specimens and 7 (77.7%) of wound swabs. *S. haemolyticus*, was isolated from 3 (15%) of blood and 12 (52.1%) of urine samples. The only isolate of *S. warneri* was from a CSF sample.

Table (2): The isolated species of CoNS from different clinical specimens (n=100).

CON species	Specimens No.									
	N	Urine	Blood	Sterile fluid	Vascular Catheter	Wound swab	CSF	High vaginal swab	Respirat. samples	Others
<i>S. epidermidis</i>	57	7	9	9	8	7	5	3	4	5
<i>S. haemolyticus</i>	24	12	3	1	2	2	1	1	1	1
<i>S. hominis</i>	8	0	6	1	1	0	0	0	0	0
<i>S. lugdunensis</i>	4	2	0	0	0	0	0	0	0	2
<i>S. sciuri</i>	3	1	0	1	0	0	0	1	0	0
<i>S. vitulinus</i>	3	1	2	0	0	0	0	0	0	0
<i>S. warneri</i>	1	0	0	0	0	0	1	0	0	0
Total	100	23	20	12	11	9	7	5	5	8

The resistance response of CoNS isolates is shown in Table (3). Among all CoNS spp., resistance to benzylpenicillin and oxacillin were 92% and 85% respectively while most effective agents were glycopeptides, linezolid, and tigecycline.

Methicillin-resistance strains of CoNS species were concluded from oxacillin resistance and positive cefoxitin screen test.^{17, 20} From the 100 isolates, 83 samples were methicillin-resistant

Table (3): Antimicrobial resistance response of CoNS isolates tested by VITEK® 2 systems.

Tested antimicrobial agent	<i>S. epidermidis</i> (n=57)	<i>S. haemolyticus</i> (n=24)	<i>S. hominis</i> (n=8)	<i>S. lugdunensis</i> (n=4)	<i>S. sciuri</i> (n=3)	<i>S. vitulinus</i> (n=3)	<i>S. warneri</i> (n=1)	Total resistance of CoNS
Benzylpenicillin	53(92.9%)	21(87.5%)	8(100%)	4(100%)	3(100%)	2(66.6%)	1(100%)	92
Oxacillin	49(85.9%)	21(87.5%)	8(100%)	1(25%)	3(100%)	2(66.6%)	1(100%)	85
Cefoxitin screen	48(84.2%)	21(87.5%)	8(100%)	0	3(100%)	2(66.6%)	1(100%)	83
Gentamicin	20(35%)	16(66.6%)	7(87.5%)	0	0	0	1(100%)	44
Moxifloxacin	9(15.7%)	7(29.1%)	6(75%)	1(25%)	0	1(33.3%)	0	24
Erythromycin	42(73.6%)	18(75%)	7(87.5%)	3(75%)	2(66.6%)	1(33.3%)	1(100%)	74
Clindamycin	20(35%)	13(54.1%)	5(62.5%)	3(75%)	0	1(33.3%)	1(100%)	43
Linezolid	0	0	0	0	0	0	0	0
Teicoplanin	0	0	0	0	0	0	0	0
Vancomycin	0	0	0	0	0	0	0	0
Tetracycline	38(66.6%)	14(58.3%)	8(100%)	2(50%)	3(100%)	0	0	65
Tigecycline	0	0	0	0	0	0	0	0
Rifampicin	12(21%)	6	2(25%)	0	0	0	1(100%)	21
Trimethoprim/sulfamethoxazole	19(33.3%)	10(41.6%)	1(12.5%)	0	0	0	0	30

Table (4) compares glycopeptide susceptibility of all CoNS species as evaluated by both VITEK[®] 2 system and E-test. All strains of CoNS 100% were susceptible to vancomycin by VITEK[®] 2 system, while only one strain showed an

intermediate susceptibility by E-test. For teicoplanin, susceptibility was 96% by VITEK[®] 2 system and 98% by E-test, while 4% and 2% were having an intermediate susceptibility by VITEK[®] 2 system and E-test respectively.

Table (4): Vancomycin and teicoplanin susceptibility of CoNS tested by VITEK[®] 2 and E-test.

Method	Response and MIC (mg/L)	Vancomycin	Teicoplanin
	Resistant		
VITEK 2 test	Vanc. >32 mg/L	0	0
E-test	Teico. >32 mg/L	0	0
	Intermediate		
VITEK 2 test	Vanc. 8-16 mg/L	0	4
E-test	Teico. >16 mg/L	1	2
	Susceptible		
VITEK 2 test	Vanc. < 4 mg/L	100	96
E-test	Teico. < 8 mg/L	99	98
Total		100	100

For inducible clindamycin test, only 11 CoNS isolates showed a positive result; five *S. haemolyticus*, three *S. epidermidis*, two *S. hominis*, and one *S. sciuri*.

Discussion

Although CoNS lack many cell-bound and secreted virulence factors possessed by *S. aureus*; yet, CoNs are capable of adhering to prosthesis and catheter surfaces, and have the ability to form biofilm. Add to that, with the widespread use of antibiotics, CoNS became one of the main pathogens causing community and healthcare-associated infections.²¹ The CoNS species from this study were isolated among all ages and both sexes; mainly from healthcare-associated infections, but also from different community-acquired infections. CoNS were isolated from a range of infections including genitourinary tract infection, bloodstream infection, catheter-related infections, wound infection, respiratory tract infection, and CNS infections. Among hospitalized patients, bloodstream and central venous catheter infections were most common infection; this was observed by Nasaj ET al.⁸ where CoNS was isolated from blood was (43%) followed by urine (36.3%), and vascular catheter (14.3%). This was also observed by Aher study

where the majority of CoNs isolates were obtained from blood cultures followed by urine samples (21%).²² The reason for such infections by CoNS is the predisposing factors such as medical devices, interventions, immune status, or critically ill patients, affinity of CoNS to prosthetic and plastic surfaces, and ability to form biofilm to establish infection. Large numbers of CoNS were also isolated from outpatient clinics, mostly from urinary tract infection, sterile body fluid, wound and vaginal swab; our observation was similar to what found by Khosravi ET al.¹⁷ In our study, CoNS were isolated from various hospital wards and from outpatient clinics. Among the hospitalized patients, CoNS isolates were obtained from ICU patients (32.7%), nephrology (30.9%), and surgical ward (18.1%). Least was from internal medicine and pediatric wards. This is comparable to Bhatt et al. study²³ but in variance with Raina et al. study where CoNS mainly isolated from pediatric ward patients (20%), then ICU patients (18.3%).¹² This may be explained

by difference in the patient's status, medical interventions and the quality of healthcare service. Species identification of CoNS showed that *S. epidermidis* then *S. haemolyticus* constituted were the commonest isolates. Similar results were shown previously by Usha et al.²⁴ This was also observed by Bora et al., where they concluded the variation in different CoNS species may be determined geographically,²³ but this may be due to variability human microbiota including CoNS and to various hospital settings owing to differences in antimicrobial pressure. In our study we had not documented any *S. saprophyticus*; this may be due to that we used VITEK[®] 2 to identify the species of CoNS in contrast to previous works using colony characteristics and other tests. CoNS commonly develop resistance to multiple antibiotics and serve as reservoir for resistance genes that can be spread to other pathogens;²⁵ the resistance of β -lactam antibiotics in CoNS is by expression of the *mecA* gene is an example.²⁶ In our study, the highest resistance rate among the CoNS isolates was against benzylpenicillin similar to Khan et al. study showing the highest resistance was exhibited to penicillin (99.5%) and ampicillin (99%).²⁷ The CoNS species in our study showed high resistance to oxacillin except for *S. lugdunensis* where only 25% were resistant to oxacillin, this was similar to studies done by^{3, 27} where all the isolates of *S. lugdunensis* were sensitive to penicillin. This study demonstrated high prevalence

Conclusion

Staphylococcus epidermidis and *Staphylococcus haemolyticus* were the main CoNS isolated from several healthcare-associated infections such as bloodstream and urinary tract infection. CoNS were also reported from community-acquired infections. Most of

of cefoxitin resistance (83%) with oxacillin resistance indicating possible methicillin resistance. Cefoxitin resistance less than among our isolates was observed in a study from Iran¹⁷ where resistance reached 65.6% (n=82), and to a previous study in which only 50.4% of their CoNS strains were reported to be cefoxitin resistant.⁵ This increasing resistance is due to extensive antibiotic use especially in our locality and accumulation of resistance genes over time. None of our CoNS strains were resistant to vancomycin, teicoplanin, linezolid, and tigecycline. Resistance to these agents is very low or rare. In our study, only one strain showed intermediately susceptibility to vancomycin (E-test) while for teicoplanin, intermediate susceptibility was observed to be 4% by VITEK[®] 2 system and 2% by E-test, indicating the development of resistance. Heterogeneous glycopeptide-intermediate staphylococci (hGIS) were previously observed over decades with E-tests¹⁰ and intermediate response is documented in this study and this may precede future resistance to glycopeptides. As founded, glycopeptides must be kept as last choice for multi-resistant staphylococci and enterococci. Inducible clindamycin test of the CoNS isolates was also performed by VITEK[®] 2 system.²⁸ In our study 11 CoNS isolates showed inducible clindamycin test, indicating the spread of inducible clindamycin resistance in our area and the need for this test if clindamycin is chosen for treatment.

the isolates showed resistance to benzylpenicillin, oxacillin, and cefoxitin; while they were susceptible to glycopeptides, linezolid, and tigecycline, but intermediate response to glycopeptide was also observed

Conflicts of interest

The author reports no conflicts of interest.

References

1. Natoli S, Fontana C, Favaro M, et al. Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options. *BMC Infect Dis.* 2009; 9(1): 83.
2. Natsis NE, Cohen PR. Coagulase-negative staphylococcus skin and soft tissue infections. *Am J Clin Dermatol.* 2018; 19(5): 671-7.
3. Singh S, Dhawan B, Kapil A, et al. Coagulase-negative staphylococci causing blood stream infection at an Indian tertiary care hospital: prevalence, antimicrobial resistance and molecular characterisation. *Indian J Med Microbiol.* 2017; 34(4): 500-5.
4. Widerström M, Wiström J, Sjöstedt A, et al. Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on *Staphylococcus epidermidis* and *Staphylococcus saprophyticus*. *Eur J Clin Microbiol Infect Dis.* 2012; 31(1): 7-20.
5. Begum ES, Anbumani N, Kalyani J, et al. Prevalence and antimicrobial susceptibility pattern of Coagulase-negative *Staphylococcus*, *Int J Med. Public Health.* 2011; 1(4): 59-62 .
6. Cremniter J, Slassi A, Quincampoix J-C, et al. Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. *J Clin Microbiol.* 2010; 48(4): 1428-31.
7. Asaad AM. Coagulase-negative *Staphylococci* clinical isolates: infectious or contaminant, that is the question. *Int J Clin Med Microbiol.* 2016; 1(101):1- 2.
8. Nasaj M, Saeidi Z, Asghari B, et al. Identification of hemolysin encoding genes and their association with antimicrobial resistance pattern among clinical isolates of coagulase-negative *Staphylococci*. *BMC Research Notes.* 2020; 13(1): 68.
9. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of *Staphylococcus aureus* heterogeneously resistant to vancomycin. *Lancet.* 1997; 350(9092): 1670-3.
10. Ahlstrand E, Svensson K, Persson L, et al. Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades. *Eur J Clin Microbiol Infect Dis.* 2011; 30(11): 1349-54.
11. Shrestha LB, Bhattarai NR, Khanal B. Antibiotic resistance and biofilm formation among coagulase-negative staphylococci isolated from clinical samples at a tertiary care hospital of eastern Nepal. *Antimicrob Resist Infect Control.* 2017; 6(1): 89.
12. Raina D, Chandola I, Negi N, et al. Prevalence of Coagulase Negative *Staphylococcus* and their Antibiotic Sensitivity Pattern from Various Clinical Samples. *J Pure Appl Microbiol.* 2020; 14(2): 1255-62.
13. Tille PM. *Bailey & Scott's Diagnostic Microbiology.* 14th edition. Missouri: Elsevier; St. Louis .2014.
14. Ibrahim YM, Abu El-Wafa WM. Evaluation of fosfomycin combined with vancomycin against vancomycin-resistant coagulase negative staphylococci. *J Chemother.* 2020; 32(8): 411-9.
15. Szczuka E, Jabłońska L, Kaznowski A. Coagulase-negative staphylococci: pathogenesis, occurrence of antibiotic resistance genes and in vitro effects of antimicrobial agents on biofilm-growing bacteria. *J Med Microbiol.* 2016; 65(12): 1405-13.
16. Kloos WE, Schleifer KH. Simplified scheme for routine identification of human *Staphylococcus* species. *J Clin Microbiol.* 1975; 1(1): 82-8.
17. Khosravi AD, Roointan M, Abbasi Montazeri E, et al. Application of tuf gene sequence analysis for the identification of species of coagulase-negative staphylococci in clinical samples and evaluation of their antimicrobial resistance pattern. *Infect Drug Resist.* 2018;11:1275-82.

18. Weinstien MP, Lewis JS, Bobenchick M et al. Performance Standards for Antimicrobial Susceptibility Testing. M100, 28th ed. Wayne, Clinical and Laboratory Standards Institute; 2018.
19. Sader HS, Pignatari AC. E-test: a novel technique for antimicrobial susceptibility testing. Sao Paulo Med J. 1994;112(4):635-8.
20. Cauwelier B, Gordts B, Descheemaeker P, Van Landuyt H. Evaluation of a disk diffusion method with cefoxitin (30 microg) for detection of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 2004;23(5):389-92.
21. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014; 27(4): 870-926.
22. Aher CS. The isolation pattern, species distribution and antibiotic susceptibility profile of coagulase negative Staphylococci: emerging opportunistic pathogens. Int J Biomed Adv Res. 2014; 5(01): 23-5.
23. Bhatt P, Tandel K, Singh A, et al. Species distribution and antimicrobial resistance pattern of Coagulase-negative Staphylococci at a tertiary care centre. Med J Armed Forces India. 2016; 72(1): 71-4.
24. Usha MG, Shwetha DC, Vishwanath G. Speciation of coagulase negative Staphylococcal isolates from clinically significant specimens and their antibiogram. Indian J Pathol Microbiol. 2013; 56(3): 258-60.
25. Otto M. Molecular basis of Staphylococcus epidermidis infections. In Seminars in immunopathology 2012; 34(2): 201-14.
26. Geha DJ, Uhl JR, Gustaferra CA, et al. Multiplex PCR for identification of methicillin-resistant staphylococci in the clinical laboratory. J Clin Microbiol. 1994; 32(7): 1768-72.
27. Khan MM, Faiz A, Ashshi AM. Clinically significant Coagulase Negative Staphylococci and their antibiotic resistance pattern in a tertiary care hospital. J Pak Med Assoc. 2014; 64(10): 1171-4.
28. Jorgensen JH, Crawford SA, McElmeel ML, et al. Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing. J Clin Microbiol. 2004; 42(4): 1800-2.